[go: up one dir, main page]

WO2005056520A8 - Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy - Google Patents

Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy

Info

Publication number
WO2005056520A8
WO2005056520A8 PCT/FI2004/000750 FI2004000750W WO2005056520A8 WO 2005056520 A8 WO2005056520 A8 WO 2005056520A8 FI 2004000750 W FI2004000750 W FI 2004000750W WO 2005056520 A8 WO2005056520 A8 WO 2005056520A8
Authority
WO
WIPO (PCT)
Prior art keywords
sstr1
active compounds
receptor subtype
somatostatin receptor
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2004/000750
Other languages
French (fr)
Other versions
WO2005056520A1 (en
Inventor
Pia Knuuttila
Harri Salo
Jussi Tomperi
Siegfried Wurster
Anna-Marja Hoffren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Juvanita Pharma Ltd Oy
Original Assignee
Juvanita Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20031824A external-priority patent/FI20031824A0/en
Application filed by Juvanita Pharma Ltd Oy filed Critical Juvanita Pharma Ltd Oy
Priority to JP2006543564A priority Critical patent/JP2007513928A/en
Priority to EP04805145A priority patent/EP1692099A1/en
Priority to CA002547863A priority patent/CA2547863A1/en
Publication of WO2005056520A1 publication Critical patent/WO2005056520A1/en
Publication of WO2005056520A8 publication Critical patent/WO2005056520A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to a group of novel somatostatin receptor subtype 1 (SSTR1) active compounds and pharmaceutical compositions comprising said compounds. Furthermore, the invention concerns the use of said compounds for the treatment or prevention of diseases or conditions responding to SSTR1 active compounds. Moreover, the invention concerns methods of targeting a tissue bearing SSTR1s either for tissue imaging or as carriers for drugs to be transported to said tissue.
PCT/FI2004/000750 2003-12-12 2004-12-09 Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy Ceased WO2005056520A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006543564A JP2007513928A (en) 2003-12-12 2004-12-09 Somatostatin receptor subtype 1 (SSTR1) active compounds and their use in therapy
EP04805145A EP1692099A1 (en) 2003-12-12 2004-12-09 Somatostatine receptor subtype 1 (sstr1) active compounds and their use in therapy
CA002547863A CA2547863A1 (en) 2003-12-12 2004-12-09 Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50907303P 2003-12-12 2003-12-12
US60/509,073 2003-12-12
FI20031824 2003-12-12
FI20031824A FI20031824A0 (en) 2003-12-12 2003-12-12 New compounds and their use in therapy

Publications (2)

Publication Number Publication Date
WO2005056520A1 WO2005056520A1 (en) 2005-06-23
WO2005056520A8 true WO2005056520A8 (en) 2005-09-15

Family

ID=34680375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2004/000750 Ceased WO2005056520A1 (en) 2003-12-12 2004-12-09 Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy

Country Status (4)

Country Link
EP (1) EP1692099A1 (en)
JP (1) JP2007513928A (en)
CA (1) CA2547863A1 (en)
WO (1) WO2005056520A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009204133B2 (en) 2008-01-09 2014-04-10 Molecular Insight Pharmaceuticals, Inc. Inhibitors of carbonic anhydrase IX
CN102159545A (en) * 2008-06-04 2011-08-17 阿斯利康(瑞典)有限公司 Small molecule leptin receptor modulators
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
HUE030681T2 (en) 2008-12-05 2017-05-29 Molecular Insight Pharm Inc Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
EP2706057B1 (en) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
BR112012000210A2 (en) 2009-06-15 2019-09-24 Molecular Insight Pharm Inc process for the production of glutamic acid heterodimers.
CA2860504A1 (en) 2012-01-06 2013-07-11 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase ix
EP3300746B1 (en) 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305846C (en) * 1998-03-26 2007-03-21 参天制药株式会社 Urea Derivatives
RU2288739C2 (en) * 2001-01-12 2006-12-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик, С.А.С. Pharmaceutical composition that inhibit vascular proliferation and method for their using
US7019109B2 (en) * 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs

Also Published As

Publication number Publication date
WO2005056520A1 (en) 2005-06-23
JP2007513928A (en) 2007-05-31
EP1692099A1 (en) 2006-08-23
CA2547863A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004112711A3 (en) Oral extended-release composition
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2007119177A3 (en) Modified release formulations and methods of treating inflammatory bowel disease
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
IL173684A0 (en) Disodium-4,4'-azo-bis-salicylate and pharmaceutical compositions containing the same
GB0222514D0 (en) Organic compounds
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2006004449A3 (en) A combination composition
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
GB2446341A (en) Method and system for transdermal drug delivery
CA2632207C (en) Use of calcitonin for the treatment of ra
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
PL1699468T3 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
WO2004081031A3 (en) Thiol-mediated drug attachment to targeting peptides
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
WO2004073627A3 (en) Novel therapeutic method and compositions for topical administration

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2547863

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004805145

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006543564

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004805145

Country of ref document: EP